Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) EBITDA Margin (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of EBITDA Margin data on record, last reported at 218.49% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 20305.0% year-over-year to 218.49%; the TTM value through Dec 2025 reached 71.99%, up 6837.0%, while the annual FY2025 figure was 77.48%, 7428.0% up from the prior year.
  • EBITDA Margin reached 218.49% in Q4 2025 per INDV's latest filing, up from 13.69% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 218.49% in Q4 2025 and bottomed at 32.44% in Q2 2024.